Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.03
MYL's Cash to Debt is ranked lower than
98% of the 692 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.66 vs. MYL: 0.03 )
Ranked among companies with meaningful Cash to Debt only.
MYL' s 10-Year Cash to Debt Range
Min: 0.02  Med: 1.98 Max: 44.56
Current: 0.03
0.02
44.56
Equity to Asset 0.41
MYL's Equity to Asset is ranked lower than
79% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. MYL: 0.41 )
Ranked among companies with meaningful Equity to Asset only.
MYL' s 10-Year Equity to Asset Range
Min: 0.19  Med: 0.76 Max: 0.92
Current: 0.41
0.19
0.92
Interest Coverage 4.06
MYL's Interest Coverage is ranked lower than
90% of the 370 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 933.44 vs. MYL: 4.06 )
Ranked among companies with meaningful Interest Coverage only.
MYL' s 10-Year Interest Coverage Range
Min: 0.83  Med: 3.59 Max: 9.19
Current: 4.06
0.83
9.19
F-Score: 6
Z-Score: 2.44
M-Score: -2.17
WACC vs ROIC
7.52%
9.80%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 16.16
MYL's Operating margin (%) is ranked higher than
75% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.76 vs. MYL: 16.16 )
Ranked among companies with meaningful Operating margin (%) only.
MYL' s 10-Year Operating margin (%) Range
Min: 2.31  Med: 18.41 Max: 36
Current: 16.16
2.31
36
Net-margin (%) 11.05
MYL's Net-margin (%) is ranked higher than
68% of the 652 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.85 vs. MYL: 11.05 )
Ranked among companies with meaningful Net-margin (%) only.
MYL' s 10-Year Net-margin (%) Range
Min: -3.53  Med: 14.33 Max: 26.04
Current: 11.05
-3.53
26.04
ROE (%) 19.57
MYL's ROE (%) is ranked higher than
82% of the 677 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.87 vs. MYL: 19.57 )
Ranked among companies with meaningful ROE (%) only.
MYL' s 10-Year ROE (%) Range
Min: -8.33  Med: 14.19 Max: 29.99
Current: 19.57
-8.33
29.99
ROA (%) 5.17
MYL's ROA (%) is ranked higher than
59% of the 697 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.99 vs. MYL: 5.17 )
Ranked among companies with meaningful ROA (%) only.
MYL' s 10-Year ROA (%) Range
Min: -2.47  Med: 7.85 Max: 18.43
Current: 5.17
-2.47
18.43
ROC (Joel Greenblatt) (%) 24.36
MYL's ROC (Joel Greenblatt) (%) is ranked higher than
68% of the 694 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.80 vs. MYL: 24.36 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MYL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 4.11  Med: 37.59 Max: 92.62
Current: 24.36
4.11
92.62
Revenue Growth (3Y)(%) 11.60
MYL's Revenue Growth (3Y)(%) is ranked higher than
63% of the 534 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.80 vs. MYL: 11.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MYL' s 10-Year Revenue Growth (3Y)(%) Range
Min: -6.1  Med: 15.55 Max: 54.5
Current: 11.6
-6.1
54.5
EBITDA Growth (3Y)(%) 11.30
MYL's EBITDA Growth (3Y)(%) is ranked higher than
60% of the 476 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.80 vs. MYL: 11.30 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
MYL' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -20  Med: 11.85 Max: 107
Current: 11.3
-20
107
EPS Growth (3Y)(%) 24.20
MYL's EPS Growth (3Y)(%) is ranked higher than
77% of the 447 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.80 vs. MYL: 24.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
MYL' s 10-Year EPS Growth (3Y)(%) Range
Min: -28.8  Med: 11.80 Max: 110.4
Current: 24.2
-28.8
110.4
» MYL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

MYL Guru Trades in Q2 2014

Pioneer Investments 226,453 sh (New)
First Eagle Investment 1,241,991 sh (+83.88%)
Mario Gabelli 13,800 sh (+6.15%)
John Hussman 50,000 sh (unchged)
John Paulson 12,130,700 sh (unchged)
Steven Cohen 83,700 sh (unchged)
Vanguard Health Care Fund 4,775,700 sh (unchged)
Andreas Halvorsen Sold Out
Louis Moore Bacon 100,000 sh (-25.46%)
Scott Black 201,925 sh (-26.46%)
Jim Simons 652,200 sh (-53.46%)
Paul Tudor Jones 4,200 sh (-99.03%)
» More
Q3 2014

MYL Guru Trades in Q3 2014

Ray Dalio 57,106 sh (New)
Paul Tudor Jones 20,015 sh (+376.55%)
Louis Moore Bacon 435,000 sh (+335.00%)
Vanguard Health Care Fund 15,444,880 sh (+223.41%)
John Paulson 12,494,700 sh (+3.00%)
Pioneer Investments 282,805 sh (unchged)
Louis Moore Bacon 350,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Steven Cohen Sold Out
Scott Black 199,406 sh (-1.25%)
Mario Gabelli 10,000 sh (-27.54%)
Jim Simons 465,200 sh (-28.67%)
First Eagle Investment 809,603 sh (-34.81%)
» More
Q4 2014

MYL Guru Trades in Q4 2014

Joel Greenblatt 673,287 sh (New)
Paul Tudor Jones 254,152 sh (+1169.81%)
Pioneer Investments 691,198 sh (+144.41%)
John Paulson 14,948,400 sh (+19.64%)
First Eagle Investment 841,779 sh (+3.97%)
Louis Moore Bacon 200,000 sh (unchged)
Mario Gabelli 10,000 sh (unchged)
John Hussman 50,000 sh (unchged)
Jim Simons Sold Out
Vanguard Health Care Fund 15,037,080 sh (-2.64%)
Ray Dalio 52,706 sh (-7.70%)
Scott Black 181,796 sh (-8.83%)
Louis Moore Bacon 36,196 sh (-91.68%)
» More
Q1 2015

MYL Guru Trades in Q1 2015

Steven Cohen 253,300 sh (New)
Tom Russo 5,850 sh (New)
Pioneer Investments 826,251 sh (+19.54%)
Vanguard Health Care Fund 15,891,898 sh (+5.68%)
Scott Black 187,570 sh (+3.18%)
Mario Gabelli 10,000 sh (unchged)
Paul Tudor Jones 125,000 sh (unchged)
John Paulson 14,948,400 sh (unchged)
John Hussman Sold Out
Ray Dalio Sold Out
Louis Moore Bacon Sold Out
First Eagle Investment 586,016 sh (-30.38%)
Paul Tudor Jones 109,447 sh (-56.94%)
Joel Greenblatt 16,021 sh (-97.62%)
» More
» Details

Insider Trades

Latest Guru Trades with MYL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on Mylan NV

Vanguard Health Care Fund Comments on Mylan NV - Mar 27, 2015

We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy.

From Vanguard Health Care Fund (Trades, Portfolio) 2014 Annual Report

Check out Vanguard Health Care Fund latest stock trades

Top Ranked Articles about Mylan NV

Tom Russo Buys 3 New Stocks in Q1
Tom Russo (Trades, Portfolio) added three new stocks to his portfolio during Q1, including an insurance and pharmaceutical company, according to GuruFocus Real Time Picks. Read more...
Vanguard Health Care Fund Comments on Mylan NV
We increased our position in this global generic pharmaceutical manufacturer as its core generic business remains steady and has benefited from selective price increases. We believe the planned acquisition of Abbott’s non-U.S. established pharmaceuticals business will augment the company’s globalization strategy. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 31.04
MYL's P/E(ttm) is ranked higher than
55% of the 469 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.80 vs. MYL: 31.04 )
Ranked among companies with meaningful P/E(ttm) only.
MYL' s 10-Year P/E(ttm) Range
Min: 7.05  Med: 23.21 Max: 112.56
Current: 31.04
7.05
112.56
Forward P/E 14.49
MYL's Forward P/E is ranked higher than
75% of the 244 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 23.58 vs. MYL: 14.49 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.70
MYL's PE(NRI) is ranked higher than
54% of the 465 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 34.50 vs. MYL: 31.70 )
Ranked among companies with meaningful PE(NRI) only.
MYL' s 10-Year PE(NRI) Range
Min: 7.05  Med: 23.50 Max: 200.11
Current: 31.7
7.05
200.11
P/B 3.64
MYL's P/B is ranked lower than
51% of the 679 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. MYL: 3.64 )
Ranked among companies with meaningful P/B only.
MYL' s 10-Year P/B Range
Min: 0.64  Med: 2.67 Max: 7.02
Current: 3.64
0.64
7.02
P/S 3.53
MYL's P/S is ranked higher than
50% of the 661 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.54 vs. MYL: 3.53 )
Ranked among companies with meaningful P/S only.
MYL' s 10-Year P/S Range
Min: 0.41  Med: 1.81 Max: 4.61
Current: 3.53
0.41
4.61
PFCF 102.81
MYL's PFCF is ranked lower than
75% of the 289 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 44.65 vs. MYL: 102.81 )
Ranked among companies with meaningful PFCF only.
MYL' s 10-Year PFCF Range
Min: 8.81  Med: 19.44 Max: 115.24
Current: 102.81
8.81
115.24
POCF 27.35
MYL's POCF is ranked higher than
52% of the 399 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 28.21 vs. MYL: 27.35 )
Ranked among companies with meaningful POCF only.
MYL' s 10-Year POCF Range
Min: 6.09  Med: 12.66 Max: 40.56
Current: 27.35
6.09
40.56
EV-to-EBIT 34.69
MYL's EV-to-EBIT is ranked lower than
58% of the 480 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.91 vs. MYL: 34.69 )
Ranked among companies with meaningful EV-to-EBIT only.
MYL' s 10-Year EV-to-EBIT Range
Min: -10.7  Med: 16.30 Max: 33
Current: 34.69
-10.7
33
PEG 3.82
MYL's PEG is ranked lower than
58% of the 245 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. MYL: 3.82 )
Ranked among companies with meaningful PEG only.
MYL' s 10-Year PEG Range
Min: 0.45  Med: 2.40 Max: 11.64
Current: 3.82
0.45
11.64
Shiller P/E 52.38
MYL's Shiller P/E is ranked lower than
62% of the 312 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 40.23 vs. MYL: 52.38 )
Ranked among companies with meaningful Shiller P/E only.
MYL' s 10-Year Shiller P/E Range
Min: 10.98  Med: 25.07 Max: 701
Current: 52.38
10.98
701
Current Ratio 1.40
MYL's Current Ratio is ranked lower than
74% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. MYL: 1.40 )
Ranked among companies with meaningful Current Ratio only.
MYL' s 10-Year Current Ratio Range
Min: 1.28  Med: 3.93 Max: 8.52
Current: 1.4
1.28
8.52
Quick Ratio 1.04
MYL's Quick Ratio is ranked lower than
73% of the 596 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.69 vs. MYL: 1.04 )
Ranked among companies with meaningful Quick Ratio only.
MYL' s 10-Year Quick Ratio Range
Min: 0.85  Med: 3.01 Max: 6.76
Current: 1.04
0.85
6.76
Days Inventory 150.90
MYL's Days Inventory is ranked lower than
68% of the 616 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 113.37 vs. MYL: 150.90 )
Ranked among companies with meaningful Days Inventory only.
MYL' s 10-Year Days Inventory Range
Min: 88.95  Med: 147.08 Max: 175.9
Current: 150.9
88.95
175.9
Days Sales Outstanding 104.95
MYL's Days Sales Outstanding is ranked lower than
73% of the 589 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 72.51 vs. MYL: 104.95 )
Ranked among companies with meaningful Days Sales Outstanding only.
MYL' s 10-Year Days Sales Outstanding Range
Min: 49.61  Med: 83.48 Max: 107.26
Current: 104.95
49.61
107.26

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.28
MYL's Price/Projected FCF is ranked higher than
57% of the 315 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.05 vs. MYL: 2.28 )
Ranked among companies with meaningful Price/Projected FCF only.
MYL' s 10-Year Price/Projected FCF Range
Min: 0.62  Med: 1.39 Max: 2.53
Current: 2.28
0.62
2.53
Price/DCF (Earnings Based) 4.04
MYL's Price/DCF (Earnings Based) is ranked lower than
82% of the 51 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.65 vs. MYL: 4.04 )
Ranked among companies with meaningful Price/DCF (Earnings Based) only.
N/A
Price/Median PS Value 1.94
MYL's Price/Median PS Value is ranked lower than
72% of the 608 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. MYL: 1.94 )
Ranked among companies with meaningful Price/Median PS Value only.
MYL' s 10-Year Price/Median PS Value Range
Min: 0.36  Med: 1.95 Max: 3.77
Current: 1.94
0.36
3.77
Price/Peter Lynch Fair Value 3.13
MYL's Price/Peter Lynch Fair Value is ranked lower than
71% of the 149 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.25 vs. MYL: 3.13 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
MYL' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.67  Med: 1.55 Max: 10.2
Current: 3.13
0.67
10.2
Earnings Yield (Greenblatt) (%) 2.95
MYL's Earnings Yield (Greenblatt) (%) is ranked higher than
60% of the 698 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. MYL: 2.95 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MYL' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 2.95  Med: 5.70 Max: 15.1
Current: 2.95
2.95
15.1
Forward Rate of Return (Yacktman) (%) 11.93
MYL's Forward Rate of Return (Yacktman) (%) is ranked higher than
61% of the 307 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.25 vs. MYL: 11.93 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
MYL' s 10-Year Forward Rate of Return (Yacktman) (%) Range
Min: 3.6  Med: 6.20 Max: 39.2
Current: 11.93
3.6
39.2

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:0R5P.UK, MYL1.Switzerland, 6MY.Germany,
Mylan NV was incorporated in Pennsylvania in 1970. The Company together with its subsidiaries, is a pharmaceutical company, which develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals. The Company offers 1,300 marketed products, to customers in 140 countries and territories. It also operates a research and development network that delivers a robust product pipeline. Additionally, the Company has a specialty business that is engaged in the respiratory and allergy therapies. It offers a range of dosage forms and delivery systems, including oral solids, topicals, liquids and semi-solids while engaging on those products that are difficult to formulate and manufacture, and typically have longer life cycles than traditional generic pharmaceuticals, including transdermal patches, high potency formulations, injectables, controlled-release and respiratory products. In addition, it offers antiretroviral therapies upon which HIV/AIDS patients in developing countries depend. The Company operates in two segments, Generics and Specialty. The generic pharmaceutical business is conducted in the U.S. and Canada, Europe, the Middle East, and Africa and India, Australia, Japan, New Zealand and Brazil. The Generics segment develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable or transdermal patch form, as well as API. The Specialty segment engages in the development, manufacture and sale of branded specialty nebulized and injectable products. The Company owns or licenses a number of patents in the U.S. and other countries covering certain products and have also developed brand names and trademarks for other products. In North America, the Company markets products directly to wholesalers, distributors, retail pharmacy chains, long-term care facilities, mail order pharmacies and GPOs. It also market its generic products indirectly to independent pharmacies, managed care organizations, hospitals, nursing homes, pharmacy benefit management companies and government entities. The Company's competitors include other generic companies and branded drug companies that continue to sell or license branded pharmaceutical products after patent expirations and other statutory expirations. In the branded space, key competitors are generally other branded drug companies that compete based on its clinical characteristics and benefits.
» More Articles for MYL

Headlines

Articles On GuruFocus.com
KEELEY All Cap Value Fund First Quarter 2015 Commentary Jun 17 2015 
Actavis Stock – A Must Have For Long-Term Investors May 27 2015 
Tom Russo Buys 3 New Stocks in Q1 May 18 2015 
Teva Puts Forth Its Best Bid To Acquire Mylan Apr 25 2015 
Teva Eyeing Mylan For $40 Billion Apr 23 2015 
CalAmp and Illumina Significant Earnings Growth; Perrigo Rebuffs Takeover Offer Apr 22 2015 
Vanguard Health Care Fund Comments on Mylan NV Mar 27 2015 
Vanguard Health Care Fund 2014 Annual Report Mar 27 2015 
Impax Laboratories Inc. Steps Into Profitable Zone Feb 26 2015 
Gilead Taking Giant Leap To Serve The Hepatitis C Market Of Developing Countries Feb 26 2015 

More From Other Websites
A New Rider in the Perrigo, Mylan, Teva Merger Merry-Go-Round Jun 30 2015
EU regulators to rule on Mylan bid for Perrigo by July 29 Jun 25 2015
Mylan eyes Tel Aviv listing if Perrigo deal goes ahead Jun 24 2015
Perrigo Going Up With Or Without Mylan, Says BMO Jun 23 2015
Mylan CFO to meet Tel Aviv bourse chief to discuss listing - source Jun 23 2015
Question for FTC: Is Mylan based at Southpointe or in the Netherlands? Jun 22 2015
Teva Announces Acquisition of 4.61% Interest in Mylan - Analyst Blog Jun 22 2015
4 Top S&P 500 Stocks to Buy Not Domiciled in the US Jun 22 2015
After Tax Inversion, Mylan Seeks Uncle Sam’s Aid in Teva Dispute Jun 19 2015
Law Firm Reed Smith Names Steven Agnoli CIO Jun 19 2015
Teva boosts stake in takeover target Mylan Jun 19 2015
Nasdaq's new record by the numbers Jun 19 2015
Teva gains standing to challenge Mylan poison pill Jun 19 2015
Teva takes 4.6 percent stake in Mylan as part of bid Jun 19 2015
Teva takes 4.6 percent stake in Mylan as part of bid Jun 19 2015
Teva Completes the Purchase of 4.61 Percent Interest in Mylan N.V. Jun 19 2015
Teva ups Mylan stake, handed setback in court ruling Jun 18 2015
Teva Bid for Mylan Could Be 'Imminent' Jun 18 2015
5 Top ADSs Seeing Big Analyst Upgrades and Downgrades Jun 18 2015
U.S. Court of Appeals for the Federal Circuit Finds Teva's '808 Copaxone® Patent Invalid Jun 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK